Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1582117 | 0.89 | KMT2A (0.54) | KMT2AMEN1HTTLMNAMAPT | |
| SCHEMBL7217092 | 0.85 | ABCG2 (0.43) | KMT2AMEN1HTTLMNAMAPT | |
| SCHEMBL1582478 | 0.82 | PTGS2 (0.40) | KMT2AMEN1HTTLMNAMAPT | |
| SCHEMBL25680046 | 0.80 | HPRT1 (0.49) | KMT2AMEN1LMNAMAPTNPC1 | |
| SCHEMBL7210897 | 0.78 | S100A4 (0.47) | KMT2AMEN1NPC1RAB9AABCG2 | |
| SCHEMBL1512032 | 0.77 | KMT2A (0.55) | KMT2AMEN1HTTLMNAMAPT | |
| SCHEMBL1164006 | 0.76 | PIN1 (0.57) | KMT2AMEN1HTTMAPTNPC1 | |
| SCHEMBL9320625 | 0.76 | KMT2A (0.46) | KMT2AMEN1MAPTHPGDALDH1A1 | |
| SCHEMBL27844725 | 0.75 | ALDH1A1 (0.59) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL1839553 | 0.74 | ALDH1A1 (0.44) | KMT2AMEN1RAB9AALDH1A1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0738717-A1 | Certain substituted pyrimidines as intermediates for production of cycloalkyl and azacycloalkyl pyrrolopyrimidines | NEUROGEN CORPORATION (US) | 1996-10-23 | — | — | EP | claimed |
| US-9353115-B2 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353115-B2 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353115-B2 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2713737-B1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS INC (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2713737-B1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20140107115-A1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107115-A1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107115-A1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| WO-2012167053-A1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| EP-0738717-A1 | Certain substituted pyrimidines as intermediates for production of cycloalkyl and azacycloalkyl pyrrolopyrimidines | NEUROGEN CORPORATION (US) | 1996-10-23 | — | — | EP | disclosed |
| US-5463054-A | Diagnosis and treatment of anxiety, sleep, seizure disorders, overdose with benzodiazepine drugs, enhancement of memory | NEUROGEN CORPORATION (US) | 1995-10-31 | — | — | US | disclosed |
| WO-1994025463-A1 | CERTAIN ARYL FUSED PYRROLOPYRIMIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1994-11-10 | — | — | WO | disclosed |
| US-5326868-A | Treatment of sleep disorders, anxiety, seizures, memory | NEUROGEN CORPORATION (US) | 1994-07-05 | — | — | US | disclosed |
| EP-0552237-A1 | CERTAIN CYCLOALKYL AND AZACYCLOALKYL PYRROLOPYRIMIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1993-07-28 | — | — | EP | disclosed |
| US-5216159-A | Preferential antagonists, agonists or inverse agonists for gamma-aminobutyric acid binding sites; anxiolytic agents; anticonvulsants; treatment of sleep disorders | NEUROGEN CORPORATION (US) | 1993-06-01 | — | — | US | disclosed |
| WO-1992006094-A1 | CERTAIN CYCLOALKYL AND AZACYCLOALKYL PYRROLOPYRIMIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1992-04-16 | — | — | WO | disclosed |
| EP-0112280-B1 | 2-ARYL-4,6-DIHALOGEN PYRIMIDINES AS ANTIDOTES FOR PROTECTING CULTIVATED PLANTS BEFORE PHYTOTOXIC DAMAGE CAUSED BY A HERBICIDE | CIBA-GEIGY AG (CH) | 1990-08-29 | — | — | EP | disclosed |
| US-4648896-A | PLANT SAFENING AGENTS | CIBA-GEIGY CORPORATION (US) | 1987-03-10 | — | — | US | disclosed |
| EP-0112280-A2 | 2-Aryl-4,6-dihalogen pyrimidines as antidotes for protecting cultivated plants before phytotoxic damage caused by a herbicide | CIBA-GEIGY AG (CH) | 1984-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107115-A1 | NOVEL IMMUNE SYSTEM MODULATORS | HLA-DRB1, CD47, MYD88 | KMT2A 1778/4885MEN1 1819/4885HTT 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.